Edgewise Therapeutics completes sale of sevasemten to Servier for USD 1.55 billion upfront, up to USD 2.65 billion total

EWTX•2026-07-13

Edgewise completes sevasemten sale and shifts to cardiovascular focus

Edgewise Therapeutics completed the sale of sevasemten and its muscular dystrophy business to Servier for USD 1.55 billion upfront.

The deal includes up to USD 1.1 billion in regulatory and commercial milestones, for total potential consideration of up to USD 2.65 billion.

The transaction shifts Edgewise to a cardiovascular focus; proceeds are expected to fund EDG-7500 development through potential approval.

A Phase 3 trial for EDG-7500 in hypertrophic cardiomyopathy is expected to start in Q4 2026, and Phase 2 for EDG-15400 in HFpEF remains on track.

Sources

Edgewise Therapeutics completes sale of sevasemten to Servier for USD 1.55 billion upfront, up to USD 2.65 billion total

Sec

Edgewise Therapeutics completes sale of sevasemten to Servier for USD 1.55 billion upfront, up to USD 2.65 billion total

Edgewise completes sevasemten sale and shifts to cardiovascular focus

Related News

HPE releases FY25 Living Progress ESG report as AI demand raises energy, security pressures

Cumulus Media promotes John Lewis to regional vice president, expands Florida oversight

Gold drops more than 1% as rising Middle East tensions add to rate-hike fears

Sources

Edgewise Therapeutics completes sale of sevasemten to Servier for USD 1.55 billion upfront, up to USD 2.65 billion total

Ameriprise flags AI bubble hallmarks as earnings test capex payoff

Rare Element Resources announces annual shareholder meeting